ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is IDEAYA Biosciences, Inc. ?
1
With a growth in Net Sales of 55.37%, the company declared Outstanding results in Dec 25
- The company has declared positive results in Jan 70 after 9 consecutive negative quarters
- OPERATING CASH FLOW(Y) Highest at USD -71.1 MM
- NET SALES(HY) Higher at USD 218.71 MM
- NET PROFIT(HY) Higher at USD 35.97 MM
2
Market Beating performance in long term as well as near term
- Along with generating 77.31% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to IDEAYA Biosciences, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is IDEAYA Biosciences, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
IDEAYA Biosciences, Inc.
77.31%
-0.28
51.98%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
62.10%
EBIT Growth (5y)
-220.19%
EBIT to Interest (avg)
-136.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.68
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.99
EV to EBIT
-15.17
EV to EBITDA
-15.62
EV to Capital Employed
6.29
EV to Sales
11.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-41.50%
ROE (Latest)
-11.11%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -71.1 MM
NET SALES(HY)
Higher at USD 218.71 MM
NET PROFIT(HY)
Higher at USD 35.97 MM
ROCE(HY)
Highest at -10.92%
-2What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -59.78 %
DEBTORS TURNOVER RATIO(HY)
Lowest at 73.2 times
Here's what is working for IDEAYA Biosciences, Inc.
Net Sales
At USD 218.71 MM has Grown at 3,024.43%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Profit
At USD 35.97 MM has Grown at 119.75%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Higher at USD 218.71 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Net Profit
Higher at USD 35.97 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -71.1 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Here's what is not working for IDEAYA Biosciences, Inc.
Debt-Equity Ratio
Highest at -59.78 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Debtors Turnover Ratio
Lowest at 73.2 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
